These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 27987632)

  • 21. On estimating costs for economic evaluation in failure time studies.
    Hallstrom AP; Sullivan SD
    Med Care; 1998 Mar; 36(3):433-6. PubMed ID: 9520967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of costs and results of the economic assessment of health interventions].
    Prieto L; Sacristán JA; Pinto JL; Badia X; Antoñanzas F; del Llano J;
    Med Clin (Barc); 2004 Mar; 122(11):423-9. PubMed ID: 15066252
    [No Abstract]   [Full Text] [Related]  

  • 23. Hospital polypharmacy.
    Stenhouse GB
    Br Med J; 1968 Feb; 1(5590):517. PubMed ID: 5643747
    [No Abstract]   [Full Text] [Related]  

  • 24. Letter: Book prices.
    Nicholas JW; Penfold JB
    Lancet; 1975 Mar; 1(7905):517-8. PubMed ID: 46980
    [No Abstract]   [Full Text] [Related]  

  • 25. The Impact of the Approach to Accounting for Age and Sex in Economic Models on Predicted Quality-Adjusted Life-Years.
    Lee D; Hart R; Burns D; McCarthy G
    Appl Health Econ Health Policy; 2024 Sep; ():. PubMed ID: 39320707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.
    Lee D; Amadi A; Sabater J; Ellis J; Johnson H; Kotapati S; McNamara S; Walker A; Cooper M; Patterson K; Roskell N; Meng Y
    Pharmacoecon Open; 2019 Mar; 3(1):43-54. PubMed ID: 29790020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy.
    Damuzzo V; Russi A; Chiumente M; Masini C; Rebesco B; Gregis F; Nozza S; Pigozzo J; Chiarion-Sileni V; Palozzo AC
    J Oncol Pharm Pract; 2019 Jun; 25(4):787-792. PubMed ID: 29444609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How much does a diabetes out-patient appointment actually cost? An argument for PLICS.
    Grant P
    J Health Organ Manag; 2015; 29(2):154-69. PubMed ID: 25800330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches.
    Clement Nee Shrive FM; Ghali WA; Donaldson C; Manns BJ
    Health Econ; 2009 Apr; 18(4):377-88. PubMed ID: 18615835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial.
    Hirst NG; Whitty JA; Synnott RL; Eley DS; Scuffham PA
    J Med Econ; 2011; 14(6):698-704. PubMed ID: 21892854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight.
    Hatswell AJ; Porter J; Lee D; Hertel N; Latimer NR
    Value Health; 2016 Dec; 19(8):1055-1058. PubMed ID: 27987632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost data assessment in multinational economic evaluations: some theory and review of published studies.
    Halliday RG; Darba J
    Appl Health Econ Health Policy; 2003; 2(3):149-55. PubMed ID: 14984280
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.